Managing Minimally Abnormal Cervical Cancer Screening Test Results
Cet article résume les recommandations 2020 concernant la prise en charge des résultats, à la limite de la normalité, des tests de dépistage du cancer du col de l'utérus (absence de pathologie anormale, présence de cellules malpighiennes atypiques de signification indéterminée, lésions malpighiennes intraépithéliales de bas grade avec et sans test HPV à haut risque positif)
The approach to cervical cancer screening has changed substantially over the past decade. Current screening strategies for individuals older than 30 years include cytology (Papanicolaou tests), testing for high-risk (oncogenic) types of human papillomavirus (hrHPV), or both (co-testing). However, various possible combinations of test results have led to complex management algorithms, especially for test results considered to be minimally abnormal, defined as results for which it is unclear whether the next step should be colposcopy (a magnified view of the cervix, often with biopsies) or close follow-up. This article provides an update for the approach to the initial management of minimally abnormal cervical cancer screening test results.
JAMA , résumé, 2019